|
🐜
|
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation.
51 auth.
Jiehui Deng,
Jiehui Deng,
Eric S. Wang,
R. Jenkins,
Shuai Li,
Ruben Dries,
Kathleen B. Yates,
Sandeep Chhabra,
Wei Huang,
Hongye Liu,
A. Aref,
E. Ivanova,
C. Paweletz,
M. Bowden,
C. Zhou,
...
G. Herter-Sprie,
J. Sorrentino,
J. Bisi,
Patrick H. Lizotte,
Ashley A. Merlino,
Max M. Quinn,
Lauren E. Bufe,
A. Yang,
Yanxi Zhang,
Hua Zhang,
P. Gao,
Ting Chen,
Megan E. Cavanaugh,
Amanda J. Rode,
Eric Haines,
P. Roberts,
J. Strum,
W. Richards,
J. Lorch,
S. Parangi,
Viswanath Gunda,
G. Boland,
R. Bueno,
Sangeetha Palakurthi,
Gordon J. Freeman,
Gordon J. Freeman,
J. Ritz,
W. Haining,
N. Sharpless,
H. Arthanari,
Geoffrey I. Shapiro,
Geoffrey I. Shapiro,
D. Barbie,
D. Barbie,
N. Gray,
Kwok-kin Wong
|
8 |
2017 |
8
🐜
|
|
🐜
|
Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck.
16 auth.
G. Hanna,
Hongye Liu,
Robert E. Jones,
A. Bacay,
Patrick H. Lizotte,
E. Ivanova,
M. Bittinger,
Megan E. Cavanaugh,
Amanda J. Rode,
J. Schoenfeld,
...
N. Chau,
R. Haddad,
J. Lorch,
Kwok-kin Wong,
R. Uppaluri,
P. Hammerman
|
5 |
2017 |
5
🐜
|
|
🐜
|
Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study
10 auth.
M. Awad,
Yvan le Bruchec,
B. Lu,
Jason Y. Ye,
J. Miller,
Patrick H. Lizotte,
...
Megan E. Cavanaugh,
Amanda J. Rode,
C. Dumitru,
A. Spira
|
4 |
2021 |
4
🐜
|
|
🐜
|
Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival
24 auth.
L. K. de Klerk,
Anuj K. Patel,
S. Derks,
E. Pectasides,
J. Augustin,
Mohamed Uduman,
Nihal Raman,
F. G. Akarca,
N. McCleary,
J. Cleary,
...
D. Rubinson,
Jeffrey W. Clark,
Bridget Fitzpatrick,
L. Brais,
Megan E. Cavanaugh,
Amanda J. Rode,
Melissa G Jean,
Patrick H. Lizotte,
Matthew Nazzaro,
Mariano Severgnini,
Hui Zheng,
C. Fuchs,
P. Enzinger,
A. Bass
|
4 |
2021 |
4
🐜
|
|
🐜
|
Effect of FAK inhibitor defactinib on tumor immune changes and tumor reductions in a phase II window of opportunity study in malignant pleural mesothelioma (MPM).
17 auth.
R. Bueno,
R. Gill,
Patrick H. Lizotte,
K. Sprott,
D. Jackman,
Julianne Barlow,
Sristi Sharma,
B. Yeap,
L. Chirieac,
A. Lebenthal,
...
Megan E. Cavanaugh,
Amanda J. Rode,
P. Kirschmeier,
D. Kwiatkowski,
Kwok-kin Wong,
W. Richards,
David R. Weaver
|
3 |
2017 |
3
🐜
|
|
🐜
|
Knockout of CBLB Greatly Enhances Anti-Tumor Activity of CAR T Cells
14 auth.
K. Hooper,
Kyle A. Havens,
Anne-Rachel F. Krostag,
M. Magee,
U. Martin,
Ankit Gupta,
Y. Smurnyy,
Lisa Pechilis,
Amanda J. Rode,
Andrew R. Chavkin,
...
S. Grande,
R. Morgan,
Jordan Jarjour,
A. Astrakhan
|
1 |
2018 |
1
🐜
|
|
🐜
|
Corrigendum: Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study
10 auth.
M. Awad,
Yvan le Bruchec,
B. Lu,
Jason Y. Ye,
J. Miller,
Patrick H. Lizotte,
...
Megan E. Cavanaugh,
Amanda J. Rode,
C. Dumitru,
A. Spira
|
0 |
2022 |
0
🐜
|
